Skip to content
HowShorted

FILANA THERAPEUTICS, INC. short interest in 2018

In 2018, FILANA THERAPEUTICS, INC.'s disclosed short interest ran from 16.72% of shares outstanding on 12 Jan 2018 to 11.80% on 31 Dec 2018, a change of -4.92 percentage points. The year's high was 35.32% on 15 Oct 2018 and its low 6.97% on 15 Aug 2018, averaging 13.40% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 21.72 days on 30 Apr 2018. Full history: FILANA THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for FILANA THERAPEUTICS, INC. in 2018

2018 in figures

Start of year
16.72% (12 Jan 2018)
End of year
11.80% (31 Dec 2018)
Change
-4.92 pp
High
35.32% (15 Oct 2018)
Low
6.97% (15 Aug 2018)
Average
13.40%
Highest days to cover
21.72 (30 Apr 2018)
SEC filings marked
8

Every report in 2018

FILANA THERAPEUTICS, INC. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201816.72%1.00
31 Jan 201814.07%6.47
15 Feb 201813.95%12.56results (8-K), 10-K filed
28 Feb 201812.08%13.78
15 Mar 201811.83%3.90
29 Mar 201810.89%11.74
13 Apr 201811.04%11.57
30 Apr 20189.90%21.72
15 May 20189.27%8.4710-Q filed, results (8-K)
31 May 20189.23%6.68
15 Jun 20188.74%6.68
29 Jun 20187.39%1.15
13 Jul 20188.08%1.06
31 Jul 20187.46%6.8510-Q filed, results (8-K)
15 Aug 20186.97%1.00
31 Aug 201816.04%1.00
14 Sep 201823.65%2.36
28 Sep 201821.71%2.81
15 Oct 201835.32%1.00
31 Oct 201815.17%2.40results (8-K), 10-Q filed
15 Nov 201814.41%4.55
30 Nov 201813.23%7.51
14 Dec 201812.64%7.46
31 Dec 201811.80%8.05

See also: FILANA THERAPEUTICS, INC.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.